4.6 Review

Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology

期刊

AMERICAN JOURNAL OF PSYCHIATRY
卷 174, 期 3, 页码 216-229

出版社

AMER PSYCHIATRIC PUBLISHING, INC
DOI: 10.1176/appi.ajp.2016.16050503

关键词

-

资金

  1. Medical Research Council (UK) [MC-A656-5QD30]
  2. Maudsley Charity [666]
  3. Brain and Behavior Research Foundation
  4. Wellcome Trust [094849/Z/10/Z]
  5. National Institute for Health Research Biomedical Research Centre at South London
  6. Maudsley NHS Foundation Trust and King's College London
  7. Janssen
  8. Lundbeck
  9. Otsuka
  10. Chiesi
  11. Roche
  12. Sunovion
  13. Takeda
  14. FAPESP (Sao Paulo Research Foundation)
  15. CNPq (National Council for Technological and Scientific Development, Brazil)
  16. AstraZeneca
  17. Eli Lilly
  18. Allergen
  19. Bristol-Myers Squibb
  20. Hospira
  21. Janssen-Cilag
  22. Pfizer
  23. Organon
  24. Servier
  25. Sanofi-Aventis
  26. Wyeth
  27. Acadia
  28. Alexza
  29. Alkermes
  30. Allergan
  31. Avanir
  32. Boehringer Ingelheim
  33. Forum
  34. Genentech
  35. Jazz
  36. Merck
  37. Medivation
  38. Mylan
  39. Neurocrine
  40. Novartis
  41. Noven
  42. Reckitt Benckiser
  43. Reviva
  44. Shire
  45. Teva
  46. Valeant
  47. Vanda
  48. Johnson Johnson
  49. FAPESP
  50. Lundbeck Foundation
  51. Central Research Labs
  52. Dainippon Sumitomo
  53. Hong Kong Health and Medical Research Grant
  54. Chinese University of Hong Kong
  55. Elsevier Japan
  56. Meiji Seika
  57. Wiley
  58. MRC [MR/L011794/1, G0700995, MR/N026063/1, MC_U120097115] Funding Source: UKRI
  59. Lundbeck Foundation [R246-2016-3237, R155-2013-16337] Funding Source: researchfish
  60. Medical Research Council [MR/N026063/1, MR/L011794/1, 1116129, MC_U120097115, G0700995] Funding Source: researchfish
  61. National Institute for Health Research [ACF-2014-18-010, ACF-2014-17-008, CL-2015-18-005] Funding Source: researchfish
  62. Wellcome Trust [200102/Z/15/Z] Funding Source: researchfish

向作者/读者索取更多资源

Objective: Research and clinical translation in schizophrenia is limited by inconsistent definitions of treatment resistance and response. To address this issue, the authors evaluated current approaches and then developed consensus criteria and guidelines. Method: A systematic review of randomized antipsychotic clinical trials in treatment-resistant schizophrenia was performed, and definitions of treatment resistance were extracted. Subsequently, consensus operationalized criteria were developed through 1) a multiphase, mixed methods approach, 2) identification of key criteria via an online survey, and 3) meetings to achieve consensus. Results: Of 2,808 studies identified, 42 met inclusion criteria. Of these, 21 studies (50%) did not provide operationalized criteria. In the remaining studies, criteria varied considerably, particularly regarding symptom severity, prior treatment duration, and antipsychotic dosage thresholds; only two studies (5%) utilized the same criteria. The consensus group identified minimum and optimal criteria, employing the following principles: 1) current symptoms of a minimum duration and severity determined by a standardized rating scale; 2) moderate or worse functional impairment; 3) prior treatment consisting of at least two different antipsychotic trials, each for a minimum duration and dosage; 4) systematic monitoring of adherence and meeting ofminimumadherence criteria; 5) ideally at least one prospective treatment trial; and 6) criteria that clearly separate responsive from treatment-resistant patients. Conclusions: There is considerable variation in current approaches to defining treatment resistance in schizophrenia. The authors present consensus guidelines that operationalize criteria for determining and reporting treatment resistance, adequate treatment, and treatment response, providing a benchmark for research and clinical translation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据